On June 23, 2026, four directors at Spyre Therapeutics, Inc. (SYRE) executed significant sales of company stock, totaling approximately $1.60 billion. Tomas Kiselak, Funds Management Llc Fairmount, Healthcare Fund Ii L.P. Fairmount, and Peter Evan Harwin each sold 4,684,781 shares at a price of $85.31 per share.
These transactions represent substantial divestitures from key company insiders. While insider selling can be attributed to various personal financial strategies such as diversification or tax planning, the synchronized and large-scale nature of these sales by multiple directors may attract market attention.
This activity follows a smaller sale by insider Michael Thomas Henderson on June 22, 2026, who sold 20,000 shares. The aggregate value of these recent insider sales highlights a notable shift in insider holdings within Spyre Therapeutics.